Comparison between Sai Life Sciences IPO and Suraksha Diagnostic IPO.
Sai Life Sciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Suraksha Diagnostic IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Sai Life Sciences IPO is up to ₹3,042.62 Cr whereas the issue size of the Suraksha Diagnostic IPO is up to ₹846.25 Cr. The final issue price of Sai Life Sciences IPO is ₹549.00 per share and of Suraksha Diagnostic IPO is ₹441.00 per share.
| Sai Life Sciences IPO | Suraksha Diagnostic IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹2 per share |
| Issue Price (Lower) | ₹522.00 per share | ₹420.00 per share |
| Issue Price (Upper) | ₹549.00 per share | ₹441.00 per share |
| Issue Price (Final) | ₹549.00 per share | ₹441.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 27 shares | 34 shares |
| Fresh Issue Size | 1,73,04,189 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹950.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 3,81,16,934 shares | 1,91,89,330 shares |
| OFS Issue Size (Amount) | up to ₹2,092.62 Cr | up to ₹846.25 Cr |
| Issue Size Total | 5,54,21,123 shares | 1,91,89,330 shares |
| Issue Size Total (Amount) | up to ₹3,042.62 Cr | up to ₹846.25 Cr |
Sai Life Sciences IPO opens on Dec 11, 2024, while Suraksha Diagnostic IPO opens on Nov 29, 2024. The closing date of Sai Life Sciences IPO and Suraksha Diagnostic IPO is Dec 13, 2024, and Dec 03, 2024, respectively.
| Sai Life Sciences IPO | Suraksha Diagnostic IPO | |
|---|---|---|
| Anchor Bid Date | Dec 10, 2024 | Nov 28, 2024 |
| Issue Open | Dec 11, 2024 | Nov 29, 2024 |
| Issue Close | Dec 13, 2024 | Dec 03, 2024 |
| Basis Of Allotment (Tentative) | Dec 16, 2024 | Dec 04, 2024 |
| Initiation of Refunds (Tentative) | Dec 17, 2024 | Dec 05, 2024 |
| Credit of Share (Tentative) | Dec 17, 2024 | Dec 05, 2024 |
| Listing date (Tentative) | Dec 18, 2024 | Dec 06, 2024 |
| Anchor Lockin End date 1 | Jan 14, 2025 | Jan 03, 2025 |
| Anchor Lockin End date 2 | Mar 15, 2025 | Mar 04, 2025 |
Sai Life Sciences IPO P/E ratio is 126.42, as compared to Suraksha Diagnostic IPO P/E ratio of 99.31.
| Sai Life Sciences IPO | Suraksha Diagnostic IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 41.82 | 61.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 35.24 | 48.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 126.42 | 99.31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹11418.63 Cr. | ₹2296.76 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 11.79% | 14.09% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 15.96% | 21.46% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.34 | ₹4.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 8.13% | 14.09% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Sai Life Sciences IPO Retail Individual Investors (RII) are offered 1,93,97,394 shares while in Suraksha Diagnostic IPO retail investors are offered 1,93,97,394 shares. Qualified Institutional Buyers (QIB) are offered 1,10,84,224 shares in Sai Life Sciences IPO and 38,37,867 shares in Suraksha Diagnostic IPO.
| Sai Life Sciences IPO | Suraksha Diagnostic IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,66,26,336 shares | 57,56,797 shares |
| Market Maker Reservation | ||
| QIB | 1,10,84,224 shares | 38,37,867 shares |
| NII | 83,13,169 shares | 28,78,400 shares |
| RII | 1,93,97,394 shares | 67,16,266 shares |
| Employee | ||
| Others | ||
| Total | 5,54,21,123 shares | 1,91,89,330 shares |
Sai Life Sciences IPO subscribed 10.27x in total, whereas Suraksha Diagnostic IPO subscribed 1.27x.
| Sai Life Sciences IPO | Suraksha Diagnostic IPO | |
|---|---|---|
| QIB (times) | 29.78x | 1.74x |
| NII (times) | 4.99x | 1.40x |
| Big NII (times) | 6.10x | 1.53x |
| Small NII (times) | 2.78x | 1.16x |
| RII (times) | 1.39x | 0.94x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 10.27x | 1.27x |
